Cargando…

Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681615/ https://www.ncbi.nlm.nih.gov/pubmed/36104307 http://dx.doi.org/10.1210/clinem/dgac506

Ejemplares similares

Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes
por: Deng, Xinru, et al.
Publicado: (2022)

Correction to: Type 1 diabetes susceptibility alleles are associated with distinct alterations in the gut microbiota
por: Mullaney, Jane A., et al.
Publicado: (2018)

Correction: Zhang et al. Fucoidan from Laminaria japonica Ameliorates Type 2 Diabetes Mellitus in Association with Modulation of Gut Microbiota and Metabolites in Streptozocin-Treated Mice. Foods 2023, 12, 33
por: Zhang, Chenxi, et al.
Publicado: (2023)

Correction to “Gut microbiota dysbiosis in Chinese children with type 1 diabetes mellitus: An observational study”
por: Liu, Xia, et al.
Publicado: (2022)

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2016)

Correction: Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis
por: Sitina, Michal, et al.
Publicado: (2023)

Correction: Helminth Colonization Is Associated with Increased Diversity of the Gut Microbiota
por: Lee, Soo Ching, et al.
Publicado: (2021)

Gut microbiota and microbiota-derived metabolites in cardiovascular diseases
por: Chen, Xiaofeng, et al.
Publicado: (2023)

Author Correction: An online atlas of human plasma metabolite signatures of gut microbiome composition
por: Dekkers, Koen F., et al.
Publicado: (2023)

Correction to: Aging progression of human gut microbiota
por: Xu, Congmin, et al.
Publicado: (2021)

Gut microbiota and plasma metabolites associated with diabetes in women with, or at high risk for, HIV infection
por: Moon, Jee-Young, et al.
Publicado: (2018)

A Metabolite Perspective on the Involvement of the Gut Microbiota in Type 2 Diabetes
por: Fu, Yifeng, et al.
Publicado: (2023)

Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus
por: Wu, Jiaqiang, et al.
Publicado: (2023)

Correction: Correction: Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes
Publicado: (2021)

Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
por: Nilsson, Kristoffer, et al.
Publicado: (2022)

Correction to: Association of gut microbiota with glycaemic traits and incident type 2 diabetes, and modulation by habitual diet: a population-based longitudinal cohort study in Chinese adults
por: Wang, Huijun, et al.
Publicado: (2022)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Correction: Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes
por: Jeannin, Anne-Caroline, et al.
Publicado: (2020)

Correction: Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Publicado: (2014)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

Gut microbiota derived metabolites in cardiovascular health and disease
por: Wang, Zeneng, et al.
Publicado: (2018)

Implication of gut microbiota metabolites in cardiovascular and metabolic diseases
por: Brial, Francois, et al.
Publicado: (2018)

Correction: Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus
por: Mwinyi, J., et al.
Publicado: (2017)

Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes
por: Matsumura, Takeshi, et al.
Publicado: (2022)

Correction to: Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice
por: Zheng, Hong, et al.
Publicado: (2021)

Author Correction: Porphyromonas gingivalis induces entero-hepatic metabolic derangements with alteration of gut microbiota in a type 2 diabetes mouse model
por: Kashiwagi, Yoichiro, et al.
Publicado: (2021)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

Correction: Gut microbiota patterns associated with somatostatin in patients undergoing pancreaticoduodenectomy: a prospective study
por: Li, Guan-Qun, et al.
Publicado: (2020)

Correction to: Associations between Gut Microbiota and Intestinal Inflammation, Permeability and Damage in Young Malawian Children
Publicado: (2022)

Effect of Benaglutide on Gut Microbiota and Fecal Metabolites in Patients with Type 2 Diabetes Mellitus
por: Han, Chen-Yu, et al.
Publicado: (2023)

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
por: Eliasson, Björn, et al.
Publicado: (2019)

Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review)
por: Zhu, Ying, et al.
Publicado: (2020)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

Correction: Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians
por: Biagi, Elena, et al.
Publicado: (2010)

Correction: Metagenomics analysis reveals features unique to Indian distal gut microbiota
Publicado: (2020)

Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
por: del Carmen Asensio Lopez, Maria, et al.
Publicado: (2020)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
por: Tsai, Hui-Ju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ogtqa3jmonmafso3lf7ldusfff